BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33288441)

  • 1. MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
    Yin W; Cheng J; Tang Z; Toruner G; Hu S; Guo M; Robinson M; Medeiros LJ; Tang G
    Clin Lung Cancer; 2021 Jul; 22(4):e512-e518. PubMed ID: 33288441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients.
    Seo AN; Park KU; Choe G; Kim WH; Kim DW; Kang SB; Lee HS
    Tumour Biol; 2015 Dec; 36(12):9813-21. PubMed ID: 26159851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
    Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
    Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer.
    Duncan DJ; Vandenberghe ME; Scott MLJ; Barker C
    PLoS One; 2019; 14(10):e0223926. PubMed ID: 31613934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
    Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
    J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
    Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
    Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
    PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
    Cappuzzo F; Marchetti A; Skokan M; Rossi E; Gajapathy S; Felicioni L; Del Grammastro M; Sciarrotta MG; Buttitta F; Incarbone M; Toschi L; Finocchiaro G; Destro A; Terracciano L; Roncalli M; Alloisio M; Santoro A; Varella-Garcia M
    J Clin Oncol; 2009 Apr; 27(10):1667-74. PubMed ID: 19255323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients.
    Wang Y; Jiang Z; Xu C; Wang H; Tan L; Su J; Wang X; Jiang D; Hou Y; Song Q
    BMC Cancer; 2019 Mar; 19(1):240. PubMed ID: 30885149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome.
    Yin W; Liu W; Guo M; Tang Z; Toruner G; Robinson M; Cheng J; Hu S; Medeiros LJ; Tang G
    Exp Mol Pathol; 2021 Feb; 118():104572. PubMed ID: 33189723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
    Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
    Dziadziuszko R; Wynes MW; Singh S; Asuncion BR; Ranger-Moore J; Konopa K; Rzyman W; Szostakiewicz B; Jassem J; Hirsch FR
    J Thorac Oncol; 2012 Feb; 7(2):340-7. PubMed ID: 22237262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
    Bubendorf L; Dafni U; Schöbel M; Finn SP; Tischler V; Sejda A; Marchetti A; Thunnissen E; Verbeken EK; Warth A; Sansano I; Cheney R; Speel EJM; Nonaka D; Monkhorst K; Hager H; Martorell M; Savic S; Kerr KM; Tan Q; Tsourti Z; Geiger TR; Kammler R; Schulze K; Das-Gupta A; Shames D; Peters S; Stahel RA;
    Lung Cancer; 2017 Sep; 111():143-149. PubMed ID: 28838386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.